VHL antibody
Principal name
VHL antibody
Alternative names for VHL antibody
Von Hippel-Lindau disease tumor suppressor, Protein G7
Ncbi ID
9606, NP_000542, NM_198156, NP_000542.1, NP_033533.1, NM_009507, NM_052801, NM_000551
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Paraffin Sections (P), ELISA (detection) (E(detection)), Frozen Sections (C), Immunoprecipitation (IP)
Background of VHL antibody
The Von Hippel-Lindau (VHL) protein is a substrate recognition component of an E3 ubiquitin ligase complex containing elongin BC (TCEB1 and TCEB2), cullin 1 (CUL1), and RING-box protein 1 (RBX1). VHL protein has been shown to exist as three distinct isoforms resulting from altertively spliced transcript variants. Loss of VHL protein function results in a domintly inherited familial cancer syndrome that manifests as angiomas of the reti, hemangioblastomas of the central nervous system, rel clear-cell carcinomas and pheochromocytomas. Under normoxic conditions, VHL directs the ubiquitylation and subsequent proteosomal degradation of the hypoxia inducible factor HIF alpha, maintaining very low levels of HIF alpha in the cell. Cellular exposure to hypoxic conditions, or loss of VHL protein function, results in increased HIF alpha protein levels and increased expression of HIF-induced gene products, many of which are angiogenesis factors such as vascular endothelial growth factor (VEGF). Thus, loss of VHL protein function is believed to contribute to the formation of highly vascular neoplasias. In addition to HIF alpha, VHL is known to regulate the ubiquitylation of several other proteins, including tat-binding protein 1 (TBP-1), the atypical protein kise C lambda (aPKC), and two subunits of the multiprotein R Polymerase II complex (RPB1 and RPB7). Interactions with elongin BC, RPB1, RPB7 and the pVHL-associated KRAB-A domain containing protein (VHLaK) suggest that VHL may also play a more direct role in transcriptiol repression.
Detection limit for recombinant GST tagged VHL is approximately 0.1ng/ml as a capture antibody.
VHL MaxPab polyclonal antibody. Western Blot analysis of VHL expression in human placenta.
Western Blot analysis of VHL expression in transfected 293T cell line (H00007428-T01) by VHL MaxPab polyclonal antibody.Lane 1: VHL transfected lysate(18.92 KDa).Lane 2: Non-transfected lysate.
Figure 1. Immunohistochemical staining using VHL antibody (AM05321PU-N) on formalin fixed, paraffin embedded human kidney tissue.
VHL polyclonal antibody ( Cat # PAB7071 ) ( 0.01 µg/ml ) staining of human ovary lysate ( 35 µg protein in RIPA buffer ) . Primary incubation was 1 hour. Detected by chemiluminescence.
Western blot analysis of HepG2 cell lysate was resolved by SDS - PAGE , transferred to PVDF membrane and probed with VHL monoclonal antibody , clone 52A11 ( 1 : 500 ) ( Cat # MAB1074 ) . Protein was visualized using a goat anti - mouse secondary antibody conjugated to HRP and an ECL detection system.
VHL MaxPab polyclonal antibody. Western Blot analysis of VHL expression in human placenta.
Western Blot analysis of VHL expression in transfected 293T cell line (H00007428-T01) by VHL MaxPab polyclonal antibody.Lane 1: VHL transfected lysate(18.92 KDa).Lane 2: Non-transfected lysate.
Immunohistochemical staining of VHL on formalin fixed, paraffin embedded human kidney tissue with VHL monoclonal antibody, clone Ig33 ( Cat # MAB1825 ).
Western blot analysis of VHL in human kidney samples ( 30 µg ) using VHL polyclonal antibody ( Cat # PAB12546 ). Lane 1 : 0.5 µg/ml primary. Lane 2 : 2 µg/ml primary.
VHL MaxPab rabbit polyclonal antibody. Western Blot analysis of VHL expression in mouse lung.
Western Blot analysis of VHL expression in transfected 293T cell line (H00007428-T02) by VHL MaxPab polyclonal antibody.Lane 1: VHL transfected lysate(19.70 KDa).Lane 2: Non-transfected lysate.
Western blot analysis of VHL antibody (C-term) (AP17826PU-N) in HepG2 cell line lysates (35ug/lane). VHL (arrow) was detected using the purified Pab.
Human HeLa; WB Suggested Anti-VHL Antibody. . Titration: 1.0 ug/ml. . Positive Control: Hela Whole Cell; VHL antibody - N-terminal region (ARP59367_P050) in Human HeLa cells using Western Blot
Western blot analysis of Von Hippel Lindau expression in HepG2 (A); HEK293T (B); A549 (C); rat brain (D) whole cell lysates.
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of Human colon tissue using anti-VHL mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506222)
Immunohistochemical staining of paraffin-embedded Carcinoma of Human lung tissue using anti-VHL mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506222)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of Human ovary tissue using anti-VHL mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506222)
Immunohistochemical staining of paraffin-embedded Human pancreas tissue within the normal limits using anti-VHL mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506222)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of Human endometrium tissue using anti-VHL mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506222)
Immunohistochemical staining of paraffin-embedded Human bladder tissue within the normal limits using anti-VHL mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506222)
Immunohistochemical staining of paraffin-embedded Human endometrium tissue within the normal limits using anti-VHL mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506222)
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VHL (RC216151, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VHL.
Immunohistochemical staining of paraffin-embedded Carcinoma of Human liver tissue using anti-VHL Rabbit Polyclonal antibody. (TA590023)
Immunohistochemical staining of paraffin-embedded Carcinoma of Human lung tissue using anti-VHL Rabbit Polyclonal antibody. (TA590023)
Immunohistochemical staining of paraffin-embedded Human prostate tissue using anti-VHL Rabbit Polyclonal antibody. (TA590023)
Immunohistochemical staining of paraffin-embedded Carcinoma of Human kidney tissue using anti-VHL Rabbit Polyclonal antibody. (TA590023)
Immunohistochemical staining of paraffin-embedded Human pancreas tissue using anti-VHL Rabbit Polyclonal antibody. (TA590023)
Immunohistochemical staining of paraffin-embedded Human lymph node tissue using anti-VHL Rabbit Polyclonal antibody. (TA590023)
Immunohistochemical staining of paraffin-embedded Carcinoma of Human thyroid tissue using anti-VHL Rabbit Polyclonal antibody. (TA590023)
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VHL (RC216151, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-VHL.
ELISA: Von Hippel Lindau Antibody
TA303127 (0.01µg/ml) staining of Human Ovary lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Predicted cell location: Cytoplasm. Positive control: Human cervical and thyroid cancer tissue. Recommended dilution: 1/50-200 The image on the left is immunohistochemistry of paraffin-embedded human cervical cancer tissue using VHL antibody at dilution 1/40, on the right is treated with the fusion protein. (Original magnification:x 200)
Predicted cell location: Cytoplasm. Positive control: Human cervical and thyroid cancer tissue. Recommended dilution: 1/50-200 The image on the left is immunohistochemistry of paraffin-embedded human thyroid cancer tissue using VHL antibody at dilution 1/40, on the right is treated with the fusion protein. (Original magnification:x200)
Predicted cell location: Cytoplasm. Positive control: Human colon and thyroid cancer tissue. Recommended dilution: 1/25-100 The image on the left is immunohistochemistry of paraffin-embedded human colon cancer tissue using VHL antibody at dilution 1/40, on the right is treated with the fusion protein. (Original magnification:x 200)
Predicted cell location: Cytoplasm. Positive control: Human colon and thyroid cancer tissue. Recommended dilution: 1/25-100 The image on the left is immunohistochemistry of paraffin-embedded human thyroid cancer tissue using VHL antibody at dilution 1/40, on the right is treated with the fusion protein. (Original magnification:x200)
Western blot analysis of VHL antibody (N-term) (Cat. #TA324848) in HepG2 cell line lysates (35ug/lane). VHL (arrow) was detected using the purified Pab.
VHL Antibody (N-term) (RB18667) IHC analysis in formalin fixed and paraffin embedded mouse brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the VHL Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.
Confocal immunofluorescent analysis of VHL Antibody (N-term)(Cat#TA324848) with HepG2 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).
VHL Antibody (N-term) (Cat. #TA324848) flow cytometric analysis of HepG2 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
Western blot analysis of extracts of various cell lines, using VHL antibody.
- Quick-Filters:
- Highly Validated (1)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA506222 | VHL antibody |
||||||
| VHL (Von Hippel Lindau) mouse monoclonal antibody, clone OTI1E1 (formerly 1E1) | |||||||
 |
Mouse | IgG2b | OTI1E1 | Purified | Hu | P, WB |
0.1 ml /
€379.00
|
| OriGene Technologies, Inc. | |||||||
 +7 additional images |
Top Selling product! Highly validated antibody!
|
||||||
| TA303127 | VHL antibody |
||||||
| Goat Polyclonal Antibody against VHL | |||||||
 |
Goat | Aff - Purified | Can, Hu, Ms, Rt | E, WB |
0.1 mg /
€360.00
|
||
| OriGene Technologies, Inc. | |||||||
| TA321159 | VHL antibody |
||||||
| Anti-VHL Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA321160 | VHL antibody |
||||||
| Anti-VHL Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA324848 | VHL (N-term) antibody |
||||||
| Rabbit polyclonal VHL Antibody (N-term) | |||||||
 |
Rabbit | Hu | WB |
0.4 ml /
€410.00
|
|||
| OriGene Technologies, Inc. | |||||||
| +3 additional images |
|||||||
| TA326834 | VHL antibody |
||||||
| Rabbit anti-VHL Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 mg /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA327866 | VHL antibody |
||||||
| Rabbit Polyclonal VHL Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | P |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| AP17826PU-N | VHL (C-term) antibody |
||||||
 |
Rabbit | Hu | WB |
0.4 ml /
€370.00
|
|||
| Acris Antibodies GmbH | |||||||
| B8450-1 | VHL antibody |
||||||
 |
Rabbit | Aff - Purified | Hu, Ms, Rt | E, P |
50 µg /
€230.00
|
||
| Assay Biotech | |||||||
| B8450-2 | VHL antibody |
||||||
|
Rabbit | Aff - Purified | Hu, Ms, Rt | E, P |
0.1 mg /
€330.00
|
||
| Assay Biotech | |||||||
CRISPR
| Catalog No. | Species | Donor Vector | |
|---|---|---|---|
| KN208875 | VHL - human gene knockout kit via CRISPR |
||
|
Human | GFP-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN208875BN | VHL - human gene knockout kit via CRISPR |
||
|
Human | mBFP-Neo |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN208875LP | VHL - human gene knockout kit via CRISPR |
||
|
Human | Luciferase-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN208875RB | VHL - human gene knockout kit via CRISPR |
||
|
Human | RFP-BSD |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN318888 | Vhl - mouse gene knockout kit via CRISPR |
||
|
Mouse | GFP-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN318888BN | Vhl - mouse gene knockout kit via CRISPR |
||
|
Mouse | mBFP-Neo |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN318888LP | Vhl - mouse gene knockout kit via CRISPR |
||
|
Mouse | Luciferase-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN318888RB | Vhl - mouse gene knockout kit via CRISPR |
||
|
Mouse | RFP-BSD |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP316151 | VHL (transcript variant 1) |
||||
| Recombinant protein of human von Hippel-Lindau tumor suppressor (VHL), transcript variant 1 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€438.00
|
|
| OriGene Technologies, Inc. | |||||
|
|||||
| TP760451 | VHL (full length, N-term HIS tag, transcript variant 1) |
||||
| Purified recombinant protein of Human von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, full length, with N-terminal HIS tag, expressed in E.Coli, 50ug | |||||
 |
Human | > 80 % Preparation: . Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
E. coli |
50 µg /
€199.00
|
|
| OriGene Technologies, Inc. | |||||
